N-[4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide | 107754-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: N-[4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide
• 英文别名: N-[4-[6-(Cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4ylmethyl]-3-methoxybenzoyl]benzenesulphonamide；cyclopentyl N-[4-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]-2,3-dihydro-1,4-benzoxazin-6-yl]carbamate
• CAS: 107754-48-3
• 化学式: C₂₉H₃₁N₃O₇S
• 分子量: 565.647
• InChiKey: JWIANSDZUAEDJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  132
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  氯甲酸环戊酯 在 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 lithium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 76.0h， 生成 N-[4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide
  参考文献：
  名称：

  Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides

  摘要：

  The dissociation constants (KB) at the LTD4 receptor on guinea pig trachea of a series of monocyclic and bicyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides have been measured. The KB was found to be remarkably tolerant of changes in the electronic constitution and lipophilicity of the bicyclic ring system (template). Thus, N-[4[[6-[[(cyclopentyloxy)carbonyl]amino]benzimidazol-1- yl]methyl]-3-methoxybenzoyl]benzenesulfonamide (11a) and N-[4-[[5-[[(cyclopentyloxy)carbonyl]amino]benzo[b]thien-3- yl]methyl]-3-methoxybenzoyl]benzene-sulfonamide (25a) had closely similar affinities (pKB, 9.20 and 9.31, respectively; LTE4 as agonist). It has been shown that the hetero-ring of the template need not be aromatic in order to achieve high affinity, since indoline 31 and 2,3-dihydrobenz-1,4-oxazines 37a-c had pKBs greater than 9. Further, it has been shown that an o-aminophenone (see 42 and Figure 3) can function as a template; the template in 42 [see iii] is bicyclic by virtue of the presence of an intramolecular hydrogen bond. In contrast, when the template is a phenyl ring (48), receptor affinity is markedly reduced. These findings support the notion that central bicyclic ring system in this family of peptidoleukotriene antagonists is a molecular feature which helps to preorganize the acylamino and acidic chains and thereby facilitate the molecular recognition event.

  DOI：

  10.1021/jm00171a043

文献信息

• Heterocyclic amide derivatives and pharmaceutical use
  申请人：ICI Americas Inc.

  公开号：US05179112A1

  公开（公告）日：1993-01-12

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及某些苯并杂环烷基脂肪酸（以及相关的四唑和酰基磺酰胺）的新型、药用酰胺衍生物（及其盐），其化学式为I，其中基团R.sup.1、R.sup.2、L、X、Y、Z、A.sup.1、Q、A.sup.2和M的含义如规范中所述。本发明还包括含有化合物I或其盐的制药组合物，以及用于后者制备的中间体的制造工艺。
• Heterocyclic amide derivatives and use
  申请人：ICI Americas Inc.

  公开号：US05030643A1

  公开（公告）日：1991-07-09

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及某些苯并杂环烷基脂肪酸（及相关的四唑和酰基磺酰胺）的新型药用酰胺衍生物（式I）及其盐，其中基团R.sup.1、R.sup.2、L、X、Y、Z、A.sup.1、Q、A.sup.2和M的含义在规范中列出。本发明还包括包含式I化合物或其盐的制药组合物，以及用于后续过程的中间体的制造工艺。 ##STR1##
• Heterocyclic amide derivatives and pharmaceutical use thereof
  申请人：Zeneca Inc.

  公开号：US05338734A1

  公开（公告）日：1994-08-16

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及一种新型的药用酰胺衍生物，其为某些苯并杂环烷基脂肪酸（及相关的四唑和酰基磺酰胺）的衍生物，其化学式为I并包括其盐，其中基团R.sup.1，R.sup.2，L，X，Y，Z，A.sup.1，Q，A.sup.2和M的含义在说明书中给出。本发明还包括制备该化合物的方法，以及用于后续过程的中间体，以及包含化合物I或其盐的制药组合物。
• Method for treating vasospastic cardiovascular diseases heterocyclic
  申请人：Zeneca Inc.

  公开号：US05583152A1

  公开（公告）日：1996-12-10

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及一种新型、具有药学意义的苯并杂环基烷酸（及相关四唑和酰基磺酰胺）的酰胺衍生物I及其盐，其中基团R.sup.1、R.sup.2、L、X、Y、Z、A.sup.1、Q、A.sup.2和M的含义如规范中所述。本发明还包括将公式I化合物或其盐纳入制药组合物中，制备该化合物的过程以及用于后续过程的中间体。 ##STR1##
• Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
  申请人：Robinson B. Cynthia

  公开号：US20050026882A1

  公开（公告）日：2005-02-03

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a leukotriene receptor antagonist for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

  一种药物或兽药组合物，包含选自脱氢表雄酮和/或脱氢表雄酮-硫酸盐或其盐的第一种活性剂和包含白三烯受体拮抗剂的第二种活性剂，用于治疗哮喘、慢性阻塞性肺病或任何其他呼吸道疾病。该组合物以各种配方和试剂盒的形式提供。本专利的产品适用于哮喘、慢性阻塞性肺病或任何其他呼吸道疾病的预防和治疗。